Pancreatic cancer trials in Sweden

In Sweden 35 Also abroad 1095

35 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Gothenburg, Lund, Stockholm, Uppsala
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 3Taking people
A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma
Where
Linköping, Lund, Stockholm
Age
18 years and over
People
588 worldwide
Run by
Incyte Corporation
See details and how to joinNCT07522073
Phase 1/2Taking people
A Study of PRMT5 Inhibitor BAY 3713372 in Participants With MTAP-deleted Solid Tumors
Where
Gothenburg, Stockholm
Age
18 years and over
People
450 worldwide
Run by
Bayer
See details and how to joinNCT06914128 · EU 2025-520623-24-00
Phase 2Taking people
Digitoxin Pancreatic cancer trial-1
Where
Skovde
Age
18 years and over
People
50
Run by
Vaestra Goetalandsregionen
See details and how to join2024-512128-12-01 · EU 2024-512128-12-01
Phase 3Taking people
A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic markers in patients with resected pancreatic carcinoma
Where
Huddinge, Linkoping, Malmo, Umea, Uppsala
Age
18 years and over
People
414 worldwide
Run by
Universitaetsklinikum Heidelberg AöR
See details and how to joinNCT05314998 · EU 2024-514682-19-00
Phase 3Not yet taking people in Sweden
Phase 3 Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC 6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma
Where
Goteborg, Malmo, Umea
Age
18 years and over
People
233 worldwide
Run by
Revolution Medicines Inc.
See details and how to join2025-524969-24-00 · EU 2025-524969-24-00
Phase 1/2Taking people
A Study to Test the Safety and Effectiveness of GSK5764227, Alone or With Other Treatments, in Participants With Advanced Gastrointestinal Cancers That Cannot be Surgically Removed (EMBOLD PanGI-201)
Where
Gothenburg, Lund, Stockholm, Uppsala
Age
18 years and over
People
346 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT06885034
Phase 1/2Taking people
Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
Where
Lund, Stockholm
Age
18 years to 130 years
People
695 worldwide
Run by
AstraZeneca
See details and how to joinNCT05417594 · EU 2023-504984-17-00
Phase 3Taking people
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Where
Goteborg, Huddinge, Umea, Vaxjo
Age
18 years and over
People
900 worldwide
Run by
Revolution Medicines, Inc.
See details and how to joinNCT07491445 · EU 2025-525088-34-00
Phase 3Taking people
Phase 3 Study of Investigator Choice of Chemotherapy with or without Zoldonrasib as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma
Where
Goteborg
Age
18 years and over
People
281 worldwide
Run by
Revolution Medicines Inc.
See details and how to join2025-524928-21-00 · EU 2025-524928-21-00
Phase 3Taking people
A Randomized, Double-Blind, Phase 3 Study of Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D–Mutated Metastatic Pancreatic Ductal Adenocarcinoma (DAWN-303)
Where
Linkoping, Lund, Solna
Age
18 years and over
People
239 worldwide
Run by
Incyte Corp.
See details and how to join2025-525009-18-00 · EU 2025-525009-18-00
No phaseTaking people
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
Where
Vänersborg
Age
18 years to 99 years
People
24,000 worldwide
Run by
AstraZeneca
See details and how to joinNCT05663515
Phase 4Taking people
Efficacy of PERT for PEI in Unresectable Pancreatic Cancer.
Where
Stockholm
Age
18 years and over
People
100 worldwide
Run by
Hospital Clinico Universitario de Santiago
See details and how to joinNCT06099119
Phase 4Taking people
Preventing postoperative complications in patients undergoing high-risk pancreatoduodenectomy with a bundle approach including hydrocortisone, ocreotide, and teres ligament patch (PANENCA): an international randomized controlled multicenter trial
Where
Goteborg, Linkoping, Lund, Stockholm
Age
18 years and over
People
460 worldwide
Run by
Amsterdam UMC Stichting
See details and how to join2024-519667-18-00 · EU 2024-519667-18-00
Phase 1/2Taking people
Master protocol of TCR-modified T cell therapy targeting HLA-restricted KRAS antigen administered in adult patients with metastatic or locally advanced PDAC
Where
Huddinge
Age
18 years and over
People
57 worldwide
Run by
Anocca AB
See details and how to join2024-513900-32-00 · EU 2024-513900-32-00
No phaseNot yet taking people in Sweden
Feasibility of the Loop Brush EUS-FNA for Characterization of Pancreatic Cysts: Pilot Clinical Investigation
Where
Umeå
Age
18 years and over
People
8
Run by
Urban Arnelo
See details and how to joinNCT07814326
No phaseTaking people
Study-group on Palliative ERCP And RFA-ablation in Metastatic and Inoperable Pancreatic Tumors
Where
Umeå
Age
18 years to 85 years
People
178
Run by
Roberto Valente
See details and how to joinNCT07191418
Phase 1Taking people
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Where
Solna
Age
18 years and over
People
914 worldwide
Run by
Seagen, a wholly owned subsidiary of Pfizer
See details and how to joinNCT06131840 · EU 2023-505858-18-00
Phase 3Taking people
Short or long NAT for BR/LAPC (ADVANTAGE Trial)
Where
Goteborg, Huddinge
Age
18 years and over
People
754 worldwide
Run by
Vastra Gotalandsregionen
See details and how to join2022-502117-29-00 · EU 2022-502117-29-00
Phase 2/3Taking people
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
Where
Solna
Age
18 years and over
People
175 worldwide
Run by
GE Healthcare
See details and how to joinNCT07219238 · EU 2024-519384-18-00
Phase 1/2Taking people
Safety and Performance of a Novel Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients With Pancreatic Cancer
Where
Solna
Age
18 years and over
People
9
Run by
Smartwise Sweden AB
See details and how to joinNCT07575191 · EU 2025-524733-11-00
No phaseNot yet taking people in Sweden
Venous Resection in Patients Undergoing Pancreatic Surgery
Where
Gothenburg
Age
18 years and over
People
1,000 worldwide
Run by
Sahlgrenska University Hospital
See details and how to joinNCT07621029
Phase 3Taking people
Intensified treatment in patients with oligometastatic pancreatic cancer - multimodal surgical treatment versus systemic chemotherapy alone: a randomized controlled trial - METAPANC
Where
Goteborg
Age
18 years and over
People
500 worldwide
Run by
Universitaetsmedizin Goettingen
See details and how to join2023-503558-10-00 · EU 2023-503558-10-00
No phaseTaking people
Pancreatic Neuroendocrine Tumour - Optimal Surgical Debulking or Not
Where
Gothenburg, Lund, Stockholm, Uppsala
Age
18 years and over
People
200
Run by
Uppsala University
See details and how to joinNCT07273409
Phase 1Taking people
IMAGINE 1
Where
Huddinge
Age
18 years and over
People
20
Run by
Karolinska University Hospital
See details and how to join2025-522290-11-00 · EU 2025-522290-11-00